Lipella Pharmaceuticals (LIPO) announced the issuance of U.S. Patent No. 12,326,492, titled “Systems and Methods of Detecting Interstitial Cystitis.” The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions. The patent covers a method, using magnetic resonance imaging, to detect lesions in body cavities. “This method can potentially provide enhanced outcome assessments to our development programs; especially mucosal disorders, including our existing programs: LP-310 for oral lichen planus, LP-10 for hemorrhagic cystitis and LP-50 for bladder cancer.” said Dr. Michael Chancellor, Chief Medical Officer.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
- Lipella Pharmaceuticals Announces 2025 Stockholders Meeting Date
- Lipella Pharmaceuticals re-signs manufacturing collab with Cook MyoSite
- Lipella Pharmaceuticals Faces Nasdaq Compliance Challenge
- Lipella Pharmaceuticals Presents Promising Phase 2a Trial Data
- Lipella Pharmaceuticals to present Phase 2a data for LP-310